OnKure Therapeutics (NASDAQ:OKUR) Lifted to “Strong-Buy” at Lifesci Capital

OnKure Therapeutics (NASDAQ:OKUR) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a note issued to investors on Thursday, Zacks.com reports.

Separately, Oppenheimer assumed coverage on shares of OnKure Therapeutics in a research report on Thursday. They set an “outperform” rating and a $35.00 price objective for the company.

OnKure Therapeutics Price Performance

Shares of OKUR stock opened at $19.00 on Thursday. The company has a market cap of $63.46 million, a price-to-earnings ratio of -1.13 and a beta of 0.21. OnKure Therapeutics has a 12-month low of $9.80 and a 12-month high of $87.20.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.